Skip to main content

Medicare Providers

Size

Pharmacy Policies

 

Pharmacy Clinical Policies

Crizanlizumab-tmca (Adakveo®) is a selectin blocker.

Cerliponase alfa (Brineura®) is a hydrolytic lysosomal N-terminal tripeptidyl peptidase.

The following are factor VIII products requiring prior authorization: human – Hemofil M®, Koate-DVI®; recombinant – Advate®, Adynovate®, Afstyla®, Eloctate®, Esperoct®, Helixate FS®, Jivi®, Kogenate FS®, Kogenate FS with Vial Adapter®, Kogenate FS with Bio-Set®, Kovaltry®, NovoEight®, Nuwiq®, Obizur®, Recombinate®, ReFacto®, Xyntha®, and Xyntha® Solofuse™.

Factor VIIa, recombinant (NovoSeven® RT) and coagulation factor VIIa (recombinant)-jncw (SevenFact®) are coagulation factors.

Patisiran (Onpattro™) is a double-stranded small interfering ribonucleic acid, formulated as a lipid complex for delivery to hepatocytes.

Mogamulizumab-kpkc (Poteligeo®) is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody.

Eculizumab (Soliris®) is a complement inhibitor.

Trientine (Syprine®) is a chelating agent.

Ravulizuamb-cwvz (Ultomiris®) is a complement inhibitor.

Golodirsen (Vyondys 53TM) is an antisense oligonucleotide.

Contact Us icon

Need help? We're here for you.

Contact Us
Y0020_WCM_164006E_M Last Updated On: 12/11/2024
Wellcare will be performing maintenance on Saturday, December 21, from 6 P.M. EDT to 8 A.M. EDT the next day. You might not be able to access systems or fax during this time. We are sorry for any issues this may cause. Thank you for your patience. If you need assistance, contact us. ×